GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global and China Osteoporosis Drugs Market, Global and China Osteoporosis Drugs Market, By Drug Type (Bisphosphonates, Alderonate, Risedronate, Ibandronate, Zoledronic Acid, Others, Calcitonin, Hormone Therapy, Selective Estrogen Receptor Modulators (SERMs), Parathyroid Hormone-Related Protein (PTHrP) Analog, Rank Ligand (RANKL) Inhibitor), Global and China Osteoporosis Drugs Market (By Route Of Adinistration: Oral, Injectable, Others), Global and China Osteoporosis Drugs Market (By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Middle East & Africa, and Asia Pacific)

Published In: 25 Mar, 2025
Code: CMI4018
Pages: 180
Formats: Excel and PDF
Industry: Pharmaceutical
- Historical Range: 2020 - 2024
- Forecast Period: 2025 - 2032

Osteoporosis is characterized by reduction in the density and quality of bones that often result in broken bones in the wrist, hip, and spine. Various factors responsible for osteoporosis include, genetic factors, low intake of calcium, magnesium, and vitamin D, eating disorders such as anorexia, inactivity and immobility, and excessive alcohol intake. Increasing approvals and launches of novel osteoporosis drugs along with increasing prevalence of osteoporasis is expected to significantly drive the osteoporosis treatment market growth over forecast period.

Key features of the study:

This report provides in-depth analysis of the Global and China Osteoporosis Drugs Market and provides market size (US$ Billion) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategy adopted by key players
It profiles key players in the Global and China Osteoporosis Drugs Market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
Key companies covered as a part of this study include, Merck & Co., Eli Lilly, Procter & Gamble, Enzo Biochem, Inc., Sanofi-Aventis, Novartis, Wyeth, Roche, GlaxoSmithKline, UCB, Amgen, BeiGene Co., Ltd., Bone Biologics, Teijin Pharma Limited, JHL Biotech Inc., Keros Therapeutics, and Taro Pharmaceuticals Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The Global and China Osteoporosis Drugs Market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global and China Osteoporosis Drugs Market

Detailed Segmentation:

Global and China Osteoporosis Drugs Market, By Drug Type:
- Bisphosphonates
  - Alendronate
  - Risedronate
  - Ibandronate
  - Zoledronic Acid
  - Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
Global and China Osteoporosis Drugs Market, By Route of Administration:
- Oral
- Injectable
- Others
Global and China Osteoporosis Drugs Market, By Distribution Channel:
- Hospitals Pharmacies
- Online Pharmacies
- Retail Pharmacies
Global and China Osteoporosis Drugs Market, By Region:
- North America
  - By Drug Type:
    - Bisphosphonates
      - Alendronate
      - Risedronate
      - Ibandronate
      - Zoledronic Acid
      - Others
    - Calcitonin
    - Hormone Therapy
    - Selective Estrogen Receptor Modulators (SERMs)
    - Parathyroid Hormone-Related Protein (PTHrP) Analog
    - Rank Ligand (RANKL) Inhibitor
  - By Route of Administration
    - Oral
    - Injectable
    - Others
  - By Distribution Channel
    - Hospitals Pharmacies
    - Online Pharmacies
    - Retail Pharmacies
  - By Country
    - U.S.
    - Canada
- Latin America
  - By Drug Type:
    - Bisphosphonates
      - Alendronate
      - Risedronate
      - Ibandronate
      - Zoledronic Acid
      - Others
    - Calcitonin
    - Hormone Therapy
    - Selective Estrogen Receptor Modulators (SERMs)
    - Parathyroid Hormone-Related Protein (PTHrP) Analog
    - Rank Ligand (RANKL) Inhibitor
  - By Route of Administration
    - Oral
    - Injectable
    - Others
  - By Distribution Channel
    - Hospitals Pharmacies
    - Online Pharmacies
    - Retail Pharmacies
  - By Country
    - Brazil
    - Mexico
    - Argentina
    - Rest of Latin America
- Europe
  - By Drug Type:
    - Bisphosphonates
      - Alendronate
      - Risedronate
      - Ibandronate
      - Zoledronic Acid
      - Others
    - Calcitonin
    - Hormone Therapy
    - Selective Estrogen Receptor Modulators (SERMs)
    - Parathyroid Hormone-Related Protein (PTHrP) Analog
    - Rank Ligand (RANKL) Inhibitor
  - By Route of Administration
    - Oral
    - Injectable
    - Others
  - By Distribution Channel
    - Hospitals Pharmacies
    - Online Pharmacies
    - Retail Pharmacies
  - By Country
    - U.K.
    - Germany
    - France
    - Spain
    - Italy
    - Russia
    - Rest of Europe
- Asia Pacific
  - By Drug Type:
    - Bisphosphonates
      - Alendronate
      - Risedronate
      - Ibandronate
      - Zoledronic Acid
      - Others
    - Calcitonin
    - Hormone Therapy
    - Selective Estrogen Receptor Modulators (SERMs)
    - Parathyroid Hormone-Related Protein (PTHrP) Analog
    - Rank Ligand (RANKL) Inhibitor
  - By Route of Administration
    - Oral
    - Injectable
    - Others
  - By Distribution Channel
    - Hospitals Pharmacies
    - Online Pharmacies
    - Retail Pharmacies
  - By Country
    - Japan
    - India
    - Australia
    - South Korea
    - ASEAN
    - Rest of Asia Pacific
- China
  - By Drug Type:
    - Bisphosphonates
      - Alendronate
      - Risedronate
      - Ibandronate
      - Zoledronic Acid
      - Others
    - Calcitonin
    - Hormone Therapy
    - Selective Estrogen Receptor Modulators (SERMs)
    - Parathyroid Hormone-Related Protein (PTHrP) Analog
    - Rank Ligand (RANKL) Inhibitor
  - By Route of Administration
    - Oral
    - Injectable
    - Others
  - By Distribution Channel
    - Hospitals Pharmacies
    - Online Pharmacies
    - Retail Pharmacies
- Middle East
  - By Drug Type:
    - Bisphosphonates
      - Alendronate
      - Risedronate
      - Ibandronate
      - Zoledronic Acid
      - Others
    - Calcitonin
    - Hormone Therapy
    - Selective Estrogen Receptor Modulators (SERMs)
    - Parathyroid Hormone-Related Protein (PTHrP) Analog
    - Rank Ligand (RANKL) Inhibitor
  - By Route of Administration
    - Oral
    - Injectable
    - Others
  - By Distribution Channel
    - Hospitals Pharmacies
    - Online Pharmacies
    - Retail Pharmacies
  - By Country
    - GCC Countries
    - Israel
    - Rest of Middle East
- Africa
  - By Drug Type:
    - Bisphosphonates
      - Alendronate
      - Risedronate
      - Ibandronate
      - Zoledronic Acid
      - Others
    - Calcitonin
    - Hormone Therapy
    - Selective Estrogen Receptor Modulators (SERMs)
    - Parathyroid Hormone-Related Protein (PTHrP) Analog
    - Rank Ligand (RANKL) Inhibitor
  - By Route of Administration
    - Oral
    - Injectable
    - Others
  - By Distribution Channel
    - Hospitals Pharmacies
    - Online Pharmacies
    - Retail Pharmacies
  - By Country
    - North Africa
    - Central Africa
    - South Africa
Company Profiles
- Merck & Co. *
  - Company Overview
  - Product Portfolio
  - Key Highlights
  - Financial Overview
  - Strategies
- Eli Lilly
- Procter & Gamble
- Enzo Biochem, Inc.
- Sanofi-Aventis
- Novartis
- Wyeth
- Roche.
- GlaxoSmithKline
- UCB
- Amgen
- BeiGene Co., Ltd.
- Bone Biologics
- Teijin Pharma Limited
- JHL Biotech Inc.
- Keros Therapeutics
- Taro Pharmaceuticals Inc.
“*” marked represents similar segmentation in other categories in the respective section.

Global and China Osteoporosis Drugs Market Detailed Segmentation:

By Drug Type:
- Bisphosphonates
  - Alendronate
  - Risedronate
  - Ibandronate
  - Zoledronic Acid
  - Others
- Calcitonin
- Hormone Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Parathyroid Hormone-Related Protein (PTHrP) Analog
- Rank Ligand (RANKL) Inhibitor
By Route of Administration:
- Oral
- Injectable
- Others
By Distribution Channel:
- Hospitall Pharmacies
- Online Pharmacies
- Retail Pharmacies
By Region:
- North America
- Europe
- Asia-Pacific
- China
- Latin America
- Middle East & Africa

Limited Time Offer - Buy Now

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports
Customize Now

Credibility and Certifications

860519526

9001:2015

27001:2022

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Download Free Sample Framework of Entire Report (Version 2025)

Interest is driven by :

Business Use – Evaluate our sample report before buying the full report

Personal Use – Explore a sample report to build knowledge

I'm not a robot

reCAPTCHA

Privacy - Terms

I acknowledge that I have read the Privacy Policy

What's Inside the Sample Report?

Current Industry Events of 2025, and Its Impact on the Market
Market Size Estimation – Historical (2020–2024), Current (2025), and Forecast (2025–2032)
Regional Breakdown – North America, Europe, Asia Pacific, Middle East, Africa, and Latin America
Country-Level Analysis – Independent cross segmental analysis across 35 countries.
Competitive Landscape – Company market share analysis, product benchmarking, and detailed Company Profiles for more than 25+ players.
Customer Intelligence – Customers profiles of more than 50 Customers
Segmental Analysis – Market Size, Y-o-Y growth rate, Trends, and use-cases across more than 5 segments, and 25 sub-segments.
Pricing Analysis – Pricing Dashboard, by geographies and by Companies.
Sustainability & Innovation Strategies – Green trends and ESG practices
Key Market Drivers, Challenges & Future Trends – Impact analysis on growth
Customized Insights Section tailored to client-specific questions or industry focus.
Future Outlook – Forecast, future positioning of companies, and futuristic trends.

GLOBAL AND CHINA OSTEOPOROSIS DRUGS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025-2032)

Global and China Osteoporosis Drugs Market Detailed Segmentation:

By Drug Type:

By Route of Administration:

By Distribution Channel:

By Region:

EXISTING CLIENTELE

Sales Office (U.S.) :

Menu

Reader Club

Help

Connect With Us :

Secure Payment By :